Monoclonal antibodies binding to different epitopes of CD20 differentially sensitize DLBCL to different classes of chemotherapy

Monoclonal antibodies binding to different epitopes of CD20 differentially sensitize DLBCL to different classes of chemotherapy

IntroductionRituximab (R), an anti-CD20 monoclonal antibody (mAb) and the world’s first approved antibody for oncology patients, was combined with the CHOP chemotherapy regimen and markedly improved the prognosis of all B- cell–derived lymphomas, the most common hematological malignancy worldwide. H...

Full description

Bibliographic Details
Main Authors: Brian Lee, Tim Pierpont, Avery August, Kristy Richards
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
rituximab
ofatumumab
chemotherapy
R-CHOP
B-cell lymphoma
DLBCL
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1159484/full

Similar Items

Similar Items